D.A. Davidson & CO. Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

D.A. Davidson & CO. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,065 shares of the biopharmaceutical company's stock after selling 11,159 shares during the quarter. D.A. Davidson & CO.'s holdings in Gilead Sciences were worth $7,963,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bridgewater Associates LP boosted its stake in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its holdings in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in shares of Gilead Sciences by 54.6% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after purchasing an additional 13,086 shares during the period. Mufg Securities Americas Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $1,699,000. Finally, Capital International Inc. CA grew its holdings in shares of Gilead Sciences by 23.8% in the fourth quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock valued at $28,839,000 after purchasing an additional 60,035 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $110.55.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the sale, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the sale, the chief financial officer owned 165,110 shares in the company, valued at $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 58,500 shares of company stock worth $6,340,745. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $0.24 during midday trading on Friday, reaching $111.28. The stock had a trading volume of 4,039,811 shares, compared to its average volume of 7,706,267. The firm has a fifty day simple moving average of $107.02 and a two-hundred day simple moving average of $104.02. Gilead Sciences, Inc. has a 12-month low of $66.34 and a 12-month high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock has a market cap of $138.42 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.